Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated versus standard BEP for intermediate and poor-risk metastatic germ cell tumours
ACTRN12613000496718Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of bleomycin, etoposide and cisplatin in germ cell tumor (GCT) (2 arms), sponsored by University of Sydney. Primary endpoint: Primary Outcome 1. Started Apr 2014; status: recruiting.
02
Drugs
bleomycinetoposidecisplatin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ACTRN12613000496718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000496718.